Evidence map›Paper›PMID 35743842›Full record

ReviewLife (Basel, Switzerland)2022

Multidrug Resistance in Cancer Cells: Focus on a Possible Strategy Plan to Address Colon Carcinoma Cells.

Chenmala Karthika, Raman Sureshkumar, Mehrukh Zehravi, Rokeya Akter, Faraat Ali, Sarker Ramproshad, Banani Mondal, Milton Kumar Kundu, Abhijit Dey, Md Habibur Rahman and 2 more

Open access · goldAbstract readReview
In one paragraph

Review in Life (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer.International journal of molecular sciences · 2025
    Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 5 countries.

Chenmala KarthikaDepartment of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty 643001, India.
Raman SureshkumarDepartment of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty 643001, India.
Mehrukh ZehraviDepartment of Clinical Pharmacy Girls Section, Prince Sattam Bin Abdul Aziz University, Alkharj 11942, Saudi Arabia.
Rokeya AkterDepartment of Global Medical Science, Wonju College of Medicine, Yonsei University, 24, Wonju 26426, Korea.
Faraat AliDepartment of Licensing and Enforcement, Laboratory Services, Botswana Medicines Regulatory Authority (BoMRA), Gaborone 999106, Botswana.ORCID 0000-0002-1438-4223
Sarker RamproshadDepartment of Pharmacy, Ranada Prasad Shaha University, Narayanganj 1400, Bangladesh.ORCID 0000-0001-9277-2451
Banani MondalDepartment of Pharmacy, Ranada Prasad Shaha University, Narayanganj 1400, Bangladesh.
Milton Kumar KunduPharmacy Discipline, Khulna University, Khulna 9208, Bangladesh.
Abhijit DeyDepartment of Life Sciences, Presidency University, Kolkata 700073, India.ORCID 0000-0002-5750-0802
Md Habibur RahmanDepartment of Global Medical Science, Wonju College of Medicine, Yonsei University, 24, Wonju 26426, Korea.ORCID 0000-0001-6099-5693
Angela AntonescuFaculty of Medicine and Pharmacy, University of Oradea, Pta 1 Decembrie 10, 410087 Oradea, Romania.
Simona CavaluFaculty of Medicine and Pharmacy, University of Oradea, Pta 1 Decembrie 10, 410087 Oradea, Romania.ORCID 0000-0001-7810-8925
JSS Academy of Higher Education and Research · INUniversity of Oradea · ROYonsei University · KRKhulna University · BDPresidency University · INPrince Sattam Bin Abdulaziz University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Even though various treatment methods are available for cancer, the death curve is not reducing. The diagnosis of cancer at the fourth stage and drug resistance are the leading reasons for treatment failure and lower survival rates. In this review article, we summarize the possible pitfalls during cancer treatment in general, which mainly include multidrug resistance, and propose a hypothesis for colorectal cancer specifically. We also evaluate multidrug resistance in cancer in general and colorectal cancer in particular and hypothesize a concept based on combination therapy with 5-fluorouracil, curcumin, and lipids for the possible management of colorectal cancer. In addition, a hypothetical approach, combining a synthetic agent and a natural chemotherapeutic agent, to treating colorectal cancer is also discussed. This hypothesis could improve the management of colorectal cancer.

Indexed as

5-fluorouracilcancercolon cancercurcuminlipidsmultidrug resistanceP-glycoprotein

Identifiers

PMID35743842
PMCPMC9224881
OpenAlexW4281679094

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.